Monthly Updates on Natalizumab-Associated Progressive Multifocal Leukoencephalopathy Available to Neurologists
Fay Ellis
In a decision that pleases neurologists, Biogen Idec, the manufacturer of natalizumab (Tysabri), is offering monthly updates of all cases of progressive multifocal leukoencephalopathy (PML) in multiple sclerosis (MS) patients taking the therapy. The information is accessible through the company’s password-protected Web site for physicians — https://medinfo.biogenidec.com — or through its toll-free medical affairs telephone line, 800 456 2255. Continue Reading
FDA Approves First Therapy to Improve Walking in MS
Fay Ellis
On Jan. 22, the FDA approved extended release tablets of dalfampridine (Ampyra) at a dose no greater than 10 mg twice a day to improve walking in multiple sclerosis (MS) patients. The approval follows the recommendation of the FDA Central Nervous System Drugs Advisory Committee, which voted last October to approve the therapy, formerly known as fampridine, in a vote of 12 to 1. Continue Reading